Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
May 31, 2022 06:00 ET
|
Eledon Pharmaceuticals, Inc.
Tegoprubart was well-tolerated, with no drug-related serious adverse eventsDose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and...
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
May 12, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with...
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
May 09, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
May 05, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
May 03, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
April 18, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
April 14, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
March 24, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation...
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
March 17, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...